How Pain Management and PM&R Practices Typically Review a Supplier
Pain management and physical medicine groups, especially those with several Kentucky locations, often route a new supplier through a compliance review before any product reaches a treatment room. That review usually covers HCT/P registration status, donor screening and testing descriptions, and a sample certificate of analysis.
Where a group includes both pain medicine and rehabilitation providers under one roof, the vendor file is often shared across both specialties once approved.
Lexington
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
160- Pain Medicine
- 78
- Physical Medicine & Rehabilitation
- 82
Account Verification and Ordering
An account opens once an NPI tied to the practice is confirmed. Pricing is disclosed only to verified accounts, and ordering is limited to licensed physicians and clinics rather than individual patients.
Cold-Chain and Shelf-Stable Shipping Options
Cryopreserved Wharton's jelly and exosome formats ship overnight on dry ice and must be stored at -80 degrees C once received, so a practice should confirm freezer capacity before the first order. Lyophilized formats are shelf-stable under normal storage conditions and do not require a cryogenic freezer, which multi-site practices sometimes prefer for simpler handling across locations.
A unique lot identifier accompanies every shipment for tracking at the patient-record level.
Documentation, Medical Director Sign-Off, and Counsel
Certificates of analysis, donor eligibility summaries, and lot release records are available to verified accounts on request. For exosome products, FDA has stated there are no FDA-approved exosome products and generally regulates them as biologic drugs; purchasing and use decisions for these products should go through the practice's own regulatory counsel.
Practices should verify their regulatory posture with the Kentucky Board of Medical Licensure and their own legal counsel before finalizing a purchasing decision.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management practice and an affiliated rehabilitation clinic share one account?+
Yes, provided both are covered under the same practice NPI used to verify the account.
What is the difference in handling between Wharton's jelly and exosome product documentation?+
Exosome products are not FDA approved and are generally regulated as biologic drugs, so questions about their classification and intended use should be reviewed separately by the practice's counsel from Wharton's jelly product questions.
How quickly can a Lexington practice receive its first shipment after account approval?+
Once the account is verified and an order is placed, cryopreserved product ships overnight on dry ice; the practice should confirm freezer readiness ahead of the scheduled delivery.